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Abstract: Prion diseases are fatal neurodegenerative conditions in humans and animals. 
In this review, we summarize the molecular background of phenotypic variability, 
relation of prion protein (PrP) to other proteins associated with neurodegenerative 
diseases, and pathogenesis of neuronal vulnerability. PrP exists in different forms that 
may be present in both diseased and non-diseased brain, however, abundant disease-
associated PrP together with tissue pathology characterizes prion diseases and associates 
with transmissibility. Prion diseases have different etiological background with distinct 
pathogenesis and phenotype. Mutations of the prion protein gene are associated with 
genetic forms. The codon 129 polymorphism in combination with the Western blot 
pattern of PrP after proteinase K digestion serves as a basis for molecular subtyping of 
sporadic Creutzfeldt-Jakob disease. Tissue damage may result from several parallel, 
interacting or subsequent pathways that involve cellular systems associated with 
synapses, protein processing, oxidative stress, autophagy, and apoptosis.  
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1. Definition of disease and objectives of the review 
 
Prion diseases are fatal disorders affecting the nervous system of several species, characterized by: 
(1) progressive loss of neurons; (2) lack of classical inflammation; (3) appearance of vacuolation in the 
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neuropil (“spongiform encephalopathy”); (4) deposition of abnormal conformers of prion protein 
(PrP); and (5) transmissibility in most forms of the disease (hence the terminology “transmissible 
spongiform encephalopathy”, TSE).  
In this review, we aim to summarize current concepts in this field: molecular background of 
phenotypic variability, relation of PrP to other proteins associated with neurodegenerative diseases, 
and pathogenesis of neuronal vulnerability. 
 
2. Phenotypic variability of human prion disease 
 
2.1. Variability of the prion protein 
 
There are various forms of PrP; recognition of these is crucial in understanding the phenotypic 
variability and pathogenesis of prion diseases. The physiological, so called cellular form of PrP (PrP
C) 
is detected in the non-diseased brain. This is detergent soluble, sensitive to proteinase-K treatment, and 
has endogenously truncated fragments. It exists generally in a full length form attached to the cell 
surface via a glycosylphosphatidylinositol anchor, however, a small amount may be endogenously (C-
terminal, N-terminal) truncated, anchorless or cytosolic. It is synthesized in the endoplasmic reticulum 
and processed in the Golgi apparatus. Its mature form is then carried to the cell surface where most of 
it is found in lipid rafts [1]. Possible physiological functions of PrP
C comprise roles in neurogenesis, 
synaptogenesis, and neuritogenesis, anti- or pro-apoptotic functions, copper binding, redox 
homeostasis, and functions of hemopoetic cells [2]. 
The major difference between PrP
C and the disease–associated form named PrP
Sc (where Sc refers 
to scrapie, a prion disease of the sheep) is a conformational change. PrP
Sc features a predominantly 
beta-pleated structure, while PrP
C is alpha-helix dominant [3]. It has generally been thought that PrP
Sc 
is detergent-insoluble and resistant to protease treatment (this form is indicated as PrP
res in Western 
blot studies) [3]. However, a conformation dependent immunoassay also detected protease–sensitive 
(PrP
sen) disease-associated transitional forms [4]. The size of disease-specific PrP
Sc aggregates ranges 
from less than 600 kDa to a very large molecular mass [5]. These small PrP
Sc aggregates were sensitive 
to proteolysis [5], moreover, the most infectious units per mass of PrP were demonstrated to be 
particles of 300-600 kDa [6]. These observations indicate that disease-associated and infectious PrP
Sc 
has protease-resistant and sensitive forms. Indeed, a novel human disease with abnormal PrP sensitive 
to protease was also recently described [7]. Moreover, PrP
C is still present in the diseased brains. The 
picture is coloured by the recent detection of detergent–insoluble and protease-resistant PrP 
(designated as PrP*) in non-diseased brains, which may be either non-infectious or may represent 
dormant infectivity [8,9]. Variability of PrP forms in diseased and non-diseased circumstances is 
summarized in Figure 1. PrP
Sc seems to be the main or only constituent of the infectious agent serving 
as basis of the ‘protein-only’ hypothesis [3,10]. The latter is debated by those arguing for the ‘not-
only-protein’ hypotheses. Without PrP
C there is no prion disease [11].  Int. J. Mol. Sci. 2009, 10                 
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Figure 1. Variability of prion protein (PrP) forms in diseased and non- 
diseased circumstances. 
 
PrP
C: physiological cellular protease sensitive PrP; PrP*: protease resistant PrP detected in non-
diseased brains; PrP
Sc: protease-resistant disease-associated PrP; PrP
Sen: disease-associated 
protease-sensitive PrP. 
 
2.2. The spectrum of human prion diseases 
 
Prion diseases may be classified according to etiology, clinicopathological phenotype, and 
constellation of the PrP gene, PRNP, and Western blot characteristics of PrP
res. Unique to prion 
diseases is that they may be triggered through infection (inoculation or dietary exposure), germline 
mutations in PRNP, and most frequently by yet unidentified “sporadic” events that generate PrP
Sc.  
Historically, human prion diseases are termed as kuru, Creutzfeldt-Jakob disease (CJD), 
Gerstmann-Sträussler-Scheinker disease (GSS), and fatal familial or sporadic insomnia (FFI or sFI). 
Generally, CJD is defined as spongiform encephalopathy, GSS as an encephalo(myelo)pathy with 
multicentric amyloid plaques, FI as predominantly thalamic degeneration with a relatively 
characteristic clinical syndrome either lacking or associated with a specific mutation in the PRNP 
(D178N associated with methionin at the polymorphic codon 129) [12,13]. 
 
2.3. Etiological classification 
 
Acquired forms comprise disorders with suspected or proven external prion exposure. This includes 
kuru, the disease of the Fore tribe in Papua-New-Guinea related to ritualistic cannibalism; iatrogenic 
CJD (iCJD), which is related to medical intervention (e.g. neurosurgery, deep electrodes, hypophyseal 
hormones, dura mater transplants); and variant CJD (vCJD) which represents dietary exposure to 
bovine spongiform encephalopathy (BSE) [14]. 
Sporadic forms of prion diseases are sporadic CJD (sCJD) and sporadic fatal insomnia (sFI). In 
these cases unequivocal demonstration of the source of infection has not yet been achieved 
(idiopathic). Int. J. Mol. Sci. 2009, 10                 
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Genetic or hereditary forms are associated with mutations in the PRNP and include  genetic CJD 
(gCJD), GSS, and FFI. Whether GSS has a sporadic (non-hereditary) counterpart still awaits 
confirmation. Cases with base pair insertions (see below) may present with distinct phenotypes, albeit 
with features overlapping with other forms. Some authors prefer to designate genetic forms with the 
mutation and not with historical names. Although many cases present as an autosomal dominant 
familial disease, lack of positive family history is frequently noted [15,16]. 
 
2.4. Summary of major clinical presentations 
 
Sporadic CJD is generally characterized by progressive dementia, visual or cerebellar disturbance, 
extrapyramidal or pyramidal dysfunction, myoclonus and in later stages, akinetic mutism. The duration 
of illness is usually around 3-6 months, and in most cases below 2 years. Most frequently the disease 
begins at the age of 60-65 years, but teenagers or individuals above 80 may be affected as well. 
Iatrogenic CJD is similar to sCJD, however in cases due to hormone treatment, cerebellar 
symptomatology may dominate. Variant CJD is characterized by early psychiatric symptoms, painful 
sensory symptoms, ataxia, myoclonus or chorea or dsystonia, and dementia. The median age at onset is 
26 (range 12-74) years, and the median duration of illness is 13.0 (6-39) months [17]. Genetic forms of 
CJD mainly resemble sCJD with longer duration of illness, but atypical presentations may be noted 
[16]. Clinical symptoms of GSS patients may be characterized by prominent, slowly progressive ataxia, 
and cognitive decline frequently associated  with pseudobulbar palsy [18]. In some mutations  spastic 
paraparesis, or parkinsonism may be prominent [16]. In fatal insomnia sleep disturbance and 
autonomic dysregulation are major features, but myoclonus and dementia are also frequent [19]. 
 
2.5. Neuropathology of human prion diseases 
 
2.5.1. Classical histopathology 
 
The classical histopathological features of prion diseases include spongiform change, neuronal loss, 
and astro- and microgliosis. Spongiform change is characterized by diffuse or focally clustered, 
occasional confluent vacuoles in the neuropil. It should be differentiated from non-specific spongiosis 
of the brain parenchyma seen in brain edema, metabolic encephalopathies, artefacts, from perineuronal 
vacuolation in acute/hypoxic damage, and spongiosis of the superficial layers of the cortex in various 
other neurodegenerative disorders [20]. Amyloid plaques (in particular multicentric plaques) are the 
prerequisite for the diagnosis of GSS, but morphologically different amyloid plaques are seen in kuru 
and vCJD. The latter is characterized by abundant amyloid plaques surrounded by vacuoles, designated 
as “florid plaques” [21]. Amyloid plaques are seen only in a less common molecular subtype (see 
below) in sCJD.  Figure 2 summarizes human prion disease forms, their major neuropathological 
features and etiology. 
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Figure 2. Overview of the spectrum of human prion diseases (microphotograph of florid 
plaque from a representative case of variant Creutzfeldt-Jakob disease,,courtesy of 
Professor James Ironside, Edinburgh, UK). 
 
 
2.5.2. PrP immunostaining patterns 
 
Since there is a lack of conformation-specific antibodies suitable for immunohistochemical studies, 
the detection of disease-associated PrP immunoreactivity requires epitope retrieval methods. In non-
diseased brains conventional immunohistochemistry for PrP reveals diffuse neuronal and neuropil 
immunostaining, which is thought to represent PrP
C. This should be distinguished from the following 
immunostaining patterns that are thought to be characteristic for prion diseases and became evident 
after specific pretreatment of sections [22]: (I) fine deposition (diffuse/synaptic pattern); (II) coarser 
depositions (these include granules, patchy/perivacuolar - deposits); (III) plaques (with amyloid Int. J. Mol. Sci. 2009, 10                 
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characteristic, eg. kuru-type and florid plaques, or without amyloid characteristic as plaque-like 
deposits, focal deposits, or so called microplaques); (IV) vascular amyloid; (V) pericellular deposits as 
dot-like and/or coarse granular immunoreactivity around unstained neuronal perikarya. In genetic 
forms of disease additional patterns may be observed [16]. It is important to distinguish PrP 
immunodeposits that show or that lack amyloid characteristics. The latter, non-amyloid deposits 
include plaque-like deposits seen only using PrP immunohistochemistry, but not with amyloid 
stainings (congo-red or thioflavine). Distinction of three major forms of PrP immunodeposits (amyloid 
versus non-amyloid fine and non-amyloid coarse) correlates well with molecular classification of sCJD 
cases (see below). In addition this concept helps in understanding the rationale of performing in vivo 
imaging for the detection of amyloid structures. Extremely rarely PrP amyloid may be detected 
predominantly or exclusively in vessel walls. This was described in a case of stop codon mutation (at 
codon 145) and also in a single sCJD case [23,24].  
And where does disease-associated PrP deposit? Co-localization immunohistochemical and 
ultrastructural studies [25,26] have indicated that it may be found in synapses, mainly chemical but 
also electric, in the neuronal cell body and dendrites (thus both post- and presynaptically), furthermore, 
in intra- and adaxonal localisations. Intracellularly they may be deposited in endosomal-lysosomal 
structures. Further localization includes macrophages and vascular associated dendritic cells in the 
vessel wall and perivascular area as well as in astrocytes and microglia.  
Deposition of disease-associated PrP is not restricted to the central nervous system in human prion 
disease. In addition to the involvement of lymphoid tissue in vCJD, other forms may harbour PrP
Sc in 
peripheral nerves, spleen, muscle tissue, neuro- and adenohypophysis [27-31]. Since the presence of 
PrP
C is a prerequisite for the deposition of PrP
Sc, and the amount of PrP
C is low in extraneural tissues, 
all circumstances leading to an upregulation of PrP
C, within the frame of its physiological roles, may 
raise the chance for PrP
C-PrP
Sc conversion. Such a situation may develop in neurogenic lesion of 
muscle tissue,
 but more prominently when chronic inflammation or granulomas in different organs lead 
to increased local production of prions [32-36]. Indeed, this phenomenon was described in a 
concomitant case of inclusion body myositis and sCJD [37]. Although prion invasion of spleen, lymph 
nodes and Peyer`s patches depend on lymphotoxin signaling, thus maintenance of follicular dendritic 
cells, the prion replicating cells within granulomas may be stromal mesenchymal cells, extending the 
spectrum of cells that may be colonized by prions [32]. In the central nervous system, co-existence of 
an inflammatory process leads to accelerated death in a mouse model of scrapie [38]. 
 
2.5.3.  Other  proteins  in  prion  diseases           
 
One of the most important aspects during the neuropathological classification of neurodegenerative 
disorders is the immunohistochemical and biochemical evaluation of protein deposits in the nervous 
system, which can be deposited intra- and extracellularly [39]. Based on the most important proteins, 
exemplified by the microtubule-associated tau, alpha-synuclein, amyloid-beta, or TAR-DNA binding 
protein-43 (TDP-43), diseases are classsified also as tauopathies, synucleinopathies, or TDP-43 
proteinopathies. Furthermore, immunostaining for ubiquitin is also of particular interest, since it 
participates in the degradation of short-lived and damaged proteins. Ubiquitin immunoreactivity is 
observed in diverse filamentous inclusions of neurodegenerative disorders. The question of the Int. J. Mol. Sci. 2009, 10                 
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involvement of other proteins than PrP can be raised in two respects; whether other proteins are also 
present in PrP deposits and how frequently are other proteinopathies associated with prion diseases.    
Hyperphosphorylated tau is the major protein in several distinct disorders (tauopathies) and is also 
an important part of the pathology of Alzheimer`s disease together with amyloid-beta deposition. In 
prion diseases, phospho-tau deposition has been described in genetic forms (mainly GSS) [18], but is 
not considered to be part of the neuropathological features of sCJD. Phospho-tau in GSS is thought to 
be identical to that in Alzheimer`s disease. A recent study reported phospho-tau-immunoreactive 
neuritic profiles clustered around PrP amyloid deposits in vCJD patients in the absence of amyloid-
beta, as well as in mouse models of vCJD [40]. Ultrastructural investigation of amyloid plaques also 
indicated that florid plaques in vCJD are rather reminiscent of neuritic plaques in Alzheimer`s disease, 
contrasting kuru plaques and multicentric plaques of CJD and GSS [41]. A recent biochemical study 
even suggested that the tau protein interacts with PrP [42]. Interestingly, the presumed PrP
C 
immunoreacts with dystrophic neurites and focally co-localizes with early but not fully developed 
disease-specific inclusions in disorders associated with prominent hyperphosphorylated tau   
pathology [22,43]. 
PrP
C immunoreactivity is observed not only in the periphery, but also throughout amyloid-beta 
plaques in Alzheimer`s disease. Whether PrP
C is involved the proteolytic processing of Amyloid 
precursor protein (APP) was adressed recently. Cellular overexpression of PrP
C inhibited the beta-
secretase cleavage of APP and reduced amyloid-beta formation [44]. Conversely, depletion of PrP
C led 
to an increase in amyloid-beta peptides. These observation indicate that indeed PrP
C may be implicated 
in the development of more frequent neurodegenerative disorders involving the abnormal accumulation 
of hyperphosporylated tau or amyloid-beta. Indeed, upregulation of PrP
C was demonstrated in cortical 
tissue of various neurodegenerative disorders [43,45].  
Granular deposition of alpha-synuclein (a protein marker of Parkinson`s disease, Lewy body 
dementia, and multiple system atrophy) was also described in sCJD, iCJD and vCJD, mainly in cases 
with longer duration of illness [46]. These deposits did not regularly co-localize with PrP
Sc deposits 
and with ubiquitin or neural markers. Interestingly, similar findigs were described in an experimental 
hamster model as well as in scrapie-affected sheep and goats [47]. 
A further protein identified recently as the major protein in certain forms of frontotemporal lobar 
degeneration as well as amyotrophic lateral sclerosis, TDP-43, was examined in prion diseases, but 
failed to support a role of this protein in the pathogenesis of prion diseases [48]. 
In human prion diseases ubiquitin immunoreactivity was found in a punctate distribution at the 
periphery of prion protein amyloid plaques and also associated with mainly coarse PrP aggregates 
[26,49]. In mouse brains infected with the ME7 scrapie strain, ubiquitination of PrP was only detected 
at the terminal stage suggesting that ubiquitination of PrP is a late event phenomenon and this 
conjugation occurs after the formation of PrP
Sc [50]. 
In contrast to other neurodegenerative disorders, intracellular ubiquitin immunoreactive inclusions 
are lacking in prion diseases, although intracellular processing of proteins related to neurodegenerative 
disorders includes several overlapping components. 
The frequency of mixed pathology is rare in CJD compared to other neurodegenerative disorders 
[51]. A systematic study aiming to assess the co-existence of Alzheimer type-pathology in CJD brains 
concluded that this most likely represents an age-related change [52]. Int. J. Mol. Sci. 2009, 10                 
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2.6. The concept of strains 
 
Infectious isolates exhibiting distinct incubation times and prion disease phenotype in the same host 
are defined as prion strains. Strains cannot be encoded by differences in the primary structure of PrP 
[53]. In conventional pathogens strains are distinguished by differences in their nucleic acid genome. 
In contrast in prion disease, this is most likely related to different conformational states of PrP that 
includes also differential proteinase K digestion kinetics [4,9]. Three principal PrP glycoforms are 
associated with prion strains; both PrP
C and PrP
Sc exists in three main glycosylation states: mono-, di- 
and unglycosylated forms [54]. These are widely used as molecular indicators of prion strain typing. 
To support the notion of strains and also the ‘protein-only’ hypothesis, so called synthetic prion strains 
have been developed and described [10]. The question arises whether these are in fact infectious prions 
or are simply capable of seeding prion protein production in hosts that have high levels of PrP
C and are 
close to develop a spontaneous disease.  
In humans the polymorphism at residue 129 constrains which prion strains may propagate, although 
the exact mode needs clarification. Diversity of prion strains has been demonstrated in several 
mammals and has been discussed also in relation with the species barrier [55]. The latter means that 
prions isolated from one species may be less infectious to other species. 
 
2.7. Genetic background of human prion diseases 
 
The human PRNP-gene (20p12-ter) encodes a product of 253 amino acids, including octapeptide 
repeats [56]. Most genetic forms are linked to point mutations (substitution) in the open reading frame. 
Additionally, a few families carry an insertion in the PRNP octapeptide repeat region between codons 
51 and 91 [57,58]. In cases with insertional mutation, 2, 4, 5, 6, 7, 8, and 9 plus octapeptides are 
encoded by 48, 96, 120, 144, 168, 192, and 216 additional base pairs, respectively. The mechanism of 
insertional mutation may be described as a multi-stage replication strand slippage. In contrast to 
trinucleotide repeat diseases, inserted mutations remain stable through generations. Although 
traditionally cases are classified either as CJD or GSS phenotype, it must be noted that both clinically 
and neuropathologically cases with insertional mutations may be atypical [16,59]. 
In addition to mutations, polymorphisms with or without established influence on phenotype are 
known. The role of the polymorphism E219K was suggested upon population based studies in Japan, 
since the ratio of heterozygotes is higher in the non-diseased [60]. Codon 129 is the best investigated 
polymorphism. Here either methionine or valine is encoded, thus, depending on the variability of 
alleles, individuals may be either methinone/valine (MV) heterozygotes, or MM, VV homozygotes. 
This polymorphism influences the phenotype and susceptibility in human prion disease forms [61-65]. 
Susceptibility is related to homozygosity and may be exemplified by the fact that 100% of vCJD cases 
with analysis of the PRNP are MM homozygotes. In the normal population heterozygotes represent 
50%, MM 39% and VV 11%. In contrast, in sCJD cases MM homozygotes represent 70% (64-81% in 
different studies). It is striking that 41% of patients younger than 49 years are VV, while 84% of 
patients above 80 years are MM homozygotes [61]. Noteworthy is the observation that population data 
from non-diseased Japanese people revealed a much higher prevalence of MM homozigosity (164/179) 
[66]. In genetic forms the codon 129 polymorphism may influence duration of illness and age at onset Int. J. Mol. Sci. 2009, 10                 
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(e.g. D178N, 144 base pair insertion) [67-69]. A further eminent instance concerns FFI and gCJD, both 
with the mutation D178N; when the mutated allele of D178N encodes methionine at codon 129, FFI 
will be observed, with highly selective vulnerability of the thalamus and lack of spongiform change, in 
contrast when valine at codon 129 is encoded with prominent neocortical spongiform change [67]. 
The codon 129 polymorphism was investigated in several disorders; in schizophrenia, mesial 
temporal lobe epilepsy, and frontotemporal lobar degeneration; an unequivocal influence was not 
demonstrated, while some studies indicate that in physiological activities like sleep, in ageing brain or 
in Alzheimer`s disease, the presence of a valine allele may have some role, although this is debated by 
others [70-79]. 
Downstream of PRNP is the Doppel (PRND) gene encoding a 179 aa protein [80]. In a certain prion 
protein gene knockout animal models an ectopic and increased expression of PRND is observed 
associated with loss of Purkinje cells and ataxia that can be rescued by deletion of Doppel from PrP 
knockout mice [81]. Further downstream is the testis specific PRNT gene. The function and relation to 
prion disease of the latter, together with the SPRN gene (10q26.3; shadoo: ”shadow of prion protein”), 
needs further clarification [80,82]. Some studies aim to clarify whether other genes have influence on 
prion diseases. One gene is apolipoprotein E; some studies indicated that the ε4 allele carries a risk, 
while others indicated that the ε2 allele is a prognostic factor [83-85]. Polymorphisms in the doppel or 
ADAM10 gene were not clearly influential either [86,87]. Others reported that polymorphisms in the 
upstream region of PRNP exon 1 may carry a risk for sCJD [88]. Recently, an increased proportion of 
TT homozygotes for the cathepsin D C224T polymorphism was reported in vCJD patients [89]. The 
influence of genes like Apolipoprotein E or cathepsin D may modify concomitant pathology (e.g. 
Alzheimer-type) and thus alter the clinical presentation. 
 
2.8. Molecular classification of human prion diseases 
 
It is well known that sCJD may present with a variety of clinical and histopathological phenotypes 
suggestive of the presence of prion strains in human disease. In addition, molecular prion strain typing 
was one indicator that vCJD is a distinct form of human prion disease [90]. Early observations 
indicated that the codon 129 polymorphism is one influential factor. This was exemplified also by 
differences of PrP immunoreactivity patterns in the cerebellum in sCJD [91]. A landmark study of 300 
individuals affected by sCJD by Piero Parchi and Pierluigi Gambetti confirmed that the codon 129 
polymorphism in combination with the Western blot pattern of PrP
res serves as a basis for molecular 
subtyping of sCJD [54]. Based on differences in electrophoretic mobility and N-terminal sequence of 
the core fragments, originally two forms of PrP
res were distinguished. Type 1 has a relative molecular 
mass of 21 kDa, and type 2 of 19 kDa. Thus according to codon 129 constellation and PrP
res type, 
sCJD is classified in at least six groups as MM, MV, VV with PrP type 1 or type 2, respectively [54]. 
Soon it was demonstrated that vCJD shows type 2 PrP
res but with a different glycoform ratio 
designated as type 2B, to be distinguished from type 2A in other forms (hence vCJD is MM type 2B) 
[22,92]. Another group identified four major types of PrP
res on Western blots from human prion 
diseases. Type 1 according to Parchi and Gambetti corresponds to type 1 and 2 by Collinge, while type 
2A is type 3, and type 2B is type 4 [90,93]. The background of differences was revisited recently. It 
was proposed that the variability of the molecular mass of PrP
res underlying the division of sCJD MM Int. J. Mol. Sci. 2009, 10                 
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type 1 into two subtypes is most likely due to pH variations during tissue preparation. Those authors 
suggested that differentiation of sCJD MM type 1 into two subgroups is not justified [94]. 
A further issue relates to the co-occurence of PrP
res  types 1 and 2 in the same brain. This 
phenomenon was already reported in the first large study and was subsequently confirmed by others 
[54,95,96]. Using antibodies presumed to recognize type 1 PrP but not type 2, patients classified as 
sCJD type 2, as well as vCJD cases, showed variable amounts of PrP
res that matched type 1 in gel 
migration characteristic [97,98]. This could mean that the two major PrP types exist in a dynamic 
equilibrium within the brain and would challenge the molecular typing of CJD based on Western blot 
signature patterns. However, others argued that this phenomenon may not be the rule and may have a 
methodological background. Using high-resolution electrophoresis and a wide range of proteinase-K 
treatment indicated that there are many type 2 CJD cases lacking evidence for co-occurrence of type 1 
PrP
res [99]. In conclusion, it seems plausible that 1) the original 6 subtypes of sCJD proposed by Parchi 
and Gambetti represents a reliable molecular classification of cases; 2) some but not all brains (around 
15-20% of cases) may contain a mixture of type 1 and type 2 PrP
res that may influence the phenotype; 
3) vCJD harbours a well distinguishable type of PrP
res.  
In sCJD patients presence of type 2 PrP
res is generally associated with a longer disease course, 
different anatomical involvement of the brain, and particularly difference in the immunomorphology of 
PrP deposits. Type 2 PrP
res is represented by more aggregated coarser deposits including plaques in 
contrast to fine appearance of PrP immunoreactivity associated with type 1 PrP
res. Further phenotype-
modifying effects of the codon 129 polymorphism are evident (Figure 3). 
These PrP Western blot patterns are detectable also in genetic forms of human prion disease. Some 
studies have shown that the glycoform ratios associated with PRNP point mutations are distinct from 
those observed in sporadic, iatrogenic and variant CJD [100]. Patients with the same PRNP mutation 
can also propagate PrP
Sc  with distinct conformations providing insight into the diverse 
clinicopathological phenotypes. GSS has an additional biochemical marker represented by low 
molecular weight bands further supporting the notion that GSS is a distinct form of prion diseases 
(“PrP amyloidosis“) [101,102]. 
Recently a novel human disease was described, which shows a distinct clinical and 
neuropathological phenotype. Since typical PrP
res was not detected, these cases were designated as 
protease-sensitive prionopathy (PsPr) [7]. 
 
3. Neuronal degeneration in prion disease 
 
The cellular pathogenesis of human prion diseased was extensively reviewed recently [103]; here 
we summarize the major processes that are important to understand the neuropathology of   
prion diseases. 
 
3.1. Pathways of prion transport 
 
The routes of infection in natural and experimental prion diseases comprise uptake of prions via the 
alimentary tract or through scarification of gums, skin, and conjunctiva, or intracerebral, 
intraperitoneal, intramuscular, or intravenous inoculation. Spread of the agent depends on their site of 
entry, strain, dose, and species and PrP genotype of the host [104]. Int. J. Mol. Sci. 2009, 10                 
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Figure 3. Differences between molecular subtypes of sporadic Creutzfeldt-Jakob disease. 
M: methionine; V: valine; NeoCx: neocortex; Bggl: basal ganglia, Thal: thalamus,   
Cbll: cerebellum.  
 Int. J. Mol. Sci. 2009, 10                 
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The following cellular and subcellular components are implicated during these processes: 1) After 
peroral challenge, the agent accumulates in lymphoid tissue, in particular gut-associated lymphoid 
tissue and draining lymph nodes, spreads to the peripheral nervous system, travels up to, and 
disseminates within, the central nervous system, and then finally spreads to peripheral sites [104].  B 
cells and follicular dendritic cells are thought to have an important role in this process [105,106].  2) 
For prion propagation in the nervous system, axonal transport, passive translocation in perineural 
lymphatics, spread in neural interspaces, and a domino-like conversion of PrP
C into PrP
Sc along neural 
cell membranes have been proposed [26,104,107]. 3) Further modes of transport involve macrophages 
and dendritic cells.  
 
3.2. Cell death pathways in prion disease 
 
Synaptic degeneration and loss are suggested to precede neuronal degeneration, in particular since 
both PrP
C and PrP
Sc locate to synapses. Early and more recent sequential studies revealed progressive 
loss of dendritic spines [108]; possibly Notch-1 may be a mediator of this process [109]. Loss of 
synapses and dendritic spines from an early stage in the disease process may have the effect of 
isolating neurons from electrical stimuli and trophic factors [108,110]. 
In various forms of prion diseases, demonstration of morphological features of apoptosis, DNA 
fragmentation, and activation of caspase-3 supports apoptosis as a relevant cell death pathway in prion 
disease. The variability of results suggests that this is not exclusive.  Another cell death process, 
autophagy, is also present as demonstrated by autophagic vacuoles in experimentally induced scrapie, 
CJD, GSS, and FFI [111]. Further studies showed that oxidative stress is a global event in prion 
disease affecting various types of neurons, while there seems to be some selective neuronal 
vulnerability (e.g. of parvalbumin immunoreactive GABAergic neurons) [112]. 
Based on the central event of protein conversion in prion diseases, several studies on pathogenesis 
investigate protein-processing systems, like the ubiquitin-proteosome system (UPS), chaperones, and 
the endosomal-lysosomal system (ELS). Neuronal cells overexpressing PrP
C develop cytosolic PrP
C 
aggregates under conditions of mild proteosome inhibition that did not cause cell death. Neuronal 
propagation of prions invoke a neurotoxic mechanism with intracellular formation of 
compartmentalized cytosolic PrP
Sc aggresomes [113]. Moreover, disease associated PrP oligomers 
inhibit the proteasome [114]. In human diseased brains cytosolic PrP
Sc aggregates have not yet been 
observed, distinguishing prion diseases from several other neurodegenerative disorders, where 
abnormal proteins aggregates are found intracellularly. However, the nuclear redistribution and 
accumulation of UPS components in sCJD, in correlation with regional tissue damage and 
demonstration of ubiquitin immunoreactivity in extracellular PrP deposits, support the notion of the 
involvement of the ubiquitin-proteosome system [115]. Distribution of neuronal immunostaining for 
ubiquitin, proteasomal subunits, and the inducible heat shock protein Hsp72 in non-diseased control 
brains suggests that “weakest-links” do exist in the brain and may be predisposed to neuronal damage 
after a yet unidentified initiating event. Chaperones, including heat shock proteins may promote or 
inhibit the formation of the pathogenic conformation. In addition, they might build up a cellular 
defense response and may contribute to save PrP
C [116]. In fact, one important component of protein 
folding homeostasis is the heat shock response that has implications for prion disease. Heat shock Int. J. Mol. Sci. 2009, 10                 
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factor 1 knockout mice infected with RML prions show similar kinetics of PrP
res accumulation, but 
they have a dramatically shortened lifespan, supporting the protective role of heat shock response 
[117]. The endosomal-lysosomal system is involved in the processing of both PrP
C and PrP
Sc, and it 
may even be the site of PrP
C–PrP
Sc transformation [2,25,118,119]. PrP
Sc may also end up in mature 
lysosomes for degradation by proteases. Indeed we demonstrated that accumulation of the lysosomal 
enzyme cathepsin D correlates with regional pathology [120]. Overloading of this system with 
undegradable PrP
Sc  might result in the failure of lysosomal functions and cytopathological 
consequences.  
Involvement of different forms of PrP in the pathogenesis has several aspects. Most likely a loss-of-
function of PrP
C (e.g. antioxidant and antiapoptotic functions) may be exacerbated by additional toxic 
gain-of-function of PrP
Sc and influenced also by further forms of PrP (e.g oligomeric) [1]. A recent 
study suggested complex interaction of the presumed toxic activity of PrP
Sc and the protective activity 
of PrP
C. It was theorized that the interaction of PrP
C with its putative coreceptor is modulated by the 
formation of a PrP
C/PrP
Sc complex, leading to a switch from stress-protective to pro-apoptotic 
signaling [121]. The issue whether toxic gain-of-function or loss-of-function mechanisms are 
responsible for pathogenicity has major therapeutic implications. In this respect, some features of 
illness associated with PrP mutations were suggested to derive from a loss of neuroprotective function 
of PrP, in contrast with a toxic gain-of-function mechanism [122]. The GPI anchor is an important 
component of PrP. Lack of this GPI anchor is associated with the presence of more PrP
Sc in an amyloid 
form, and this leads to less infectivity and neurodegeneration [123]. Transient non-PrP
Sc neurotoxic 
components may be also considered for the pathogenesis [124]. Further forms of PrP have also 
implication for the pathogenesis. Toxicity of PrP located in the cytosol was discussed and reviewed 
recently [125,126]. These toxic PrPs most likely exert their damage through interactions with a variety 
of proteins. An example is the observation of an association of cytosolic PrP with the anti-apoptotic 
protein Bcl-2, a process modulated by cytosolic chaperones including Hsp70 [127]. 
The complex cellular pathogenesis of prion diseases is supported by further neuronal as well as glial 
pathways. Terminal complement activation was demonstrated in human prion disease [128]. 
Complement activation may lead either to sublytic levels of C5b-9 that may generate oxidative stress 
and induce apoptotic cell death, or to direct cell lysis with consecutive tissue damage. The role of the 
membrane attack complex as a decisive factor for neuronal death was questioned in an experiment with 
C5-deficient mice [129]. Endoplasmic reticulum response to cellular stress conditions, termed unfolded 
protein response, is considered in the pathogenesis of neurodegenerative disorders. In human brains 
PERK, which launches the most immediate response to ER stress, were not found to be activated in 
human and experimental prion diseases, in contrast to Alzheimer’s disease [130]. Indeed, in an XBP-1 
(X-box-binding protein, a key transcriptional regulator of the unfolded protein response) knockout 
mice infected with murine prions neither prion aggregation, neuronal loss, nor survival was   
affected [131].  
Astrocytosis and microglia activation is a prominent feature of prion diseases [103]. Upregulation of 
astrocytic enzymes follows the rise in PrP, suggesting that the astrocytic response is induced by PrP
Sc. 
Studies suggest that microglia may process or degrade PrP
Sc. An interesting aspect of astroglia and 
microglia response was highlighted in the chemokine receptor CXCR3 deficient mice infected with 
prions [132]. In this model microglia activation was attenuated together with excessive astrogliosis and Int. J. Mol. Sci. 2009, 10                 
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accelerated accumulation of PrP
Sc, whereas survival times were significantly prolonged; thus a novel 
disease-modifying host factor related to micro- and astroglia response was identified. 
As briefly summarized above, many proteins and pathways have been implicated in the 
pathogenesis of prion diseases. Analyses of gene expression have been performed in order to show 
what might be important. Inactivation, absence, or overexpression of a gene may affect prion 
replication if it contributes to pathogenesis. A recent systematic study tested 20 candidate genes and 
suggested that most do not significantly affect survival times, whereas ablation of amyloid precursor 
protein or interleukin-1, and overexpression of human superoxide dismutase 1, prolong incubation 
times between 13-19% [133]. These observations also emphasize a general fact in research on prion 
diseases, that the genetic background of the animal model, the prion strain, inoculum titers, and route 
of infection may all impact on the results that thus must be interpreted with caution when considering 
for relevance to human prion diseases. 
 
4. Summary 
 
The following features characterize human prion diseases: 
1.  PrP exists in different and overlapping forms in diseased and non-diseased brains; however, 
abundant disease-associated PrP together with tissue pathology characterizes prion diseases 
and associates with transmissibility. 
2.  Different etiological forms of prion disease differ in pathogenesis, which has implications for 
public health, clinical differential diagnosis, research, spread of infectivity within the body, and 
also therapeutic approaches. 
3.  In diseased brain PrP is the major protein that deposits mainly extracellularly in the brain; 
however, other proteins associated with other neurodegenerative disorders, in particular 
hyperphosphorylated tau, amyloid-beta, and alpha-synuclein may be deposited as well. The 
exact interactions of these proteins await clarification.  
4.  Mutations of the PRNP are associated with genetic forms; however the polymorphism at codon 
129 has a crucial influence on phenotype and susceptibility and may have implications for 
other non-prion disorders. 
5.  The codon 129 polymorphism in combination with the Western blot pattern of PrP after 
proteinase K digestion remains as a basis for molecular subtyping of sCJD. This represents 
strains in human prion disease. 
6.  Tissue damage may result from several parallel, interacting or subsequent pathways that 
involve cellular systems associated with synapses, protein processing, oxidative stress, 
autophagy, and apoptosis.   
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